The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zakroyshchikova I.V.

Research center of Neurology

Simaniv T.O.

Research Center of Neurology

Zemlyanaya D.O.

Pirogov Russian National Research Medical University

Timofeeva A.A.

Pirogov Russian National Research Medical University

Zakharova M.N.

Research Center of Neurology

The effect of pregnancy on multiple sclerosis

Authors:

Zakroyshchikova I.V., Simaniv T.O., Zemlyanaya D.O., Timofeeva A.A., Zakharova M.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7‑2): 43‑49

DOI: 10.17116/jnevro202412407243

Read: 1617 times

Download PDF (RU)
Contact the author
Table of contents

THE EFFECT OF PREGNANCY ON MULTIPLE SCLEROSIS
THE EFFECT OF PREGNANCY ON MULTIPLE SCLEROSIS

To cite this article:

Zakroyshchikova IV, Simaniv TO, Zemlyanaya DO, Timofeeva AA, Zakharova MN. The effect of pregnancy on multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7‑2):43‑49. (In Russ.)
https://doi.org/10.17116/jnevro202412407243

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Local cyto­kine profile of the endo­metrium in patients with repeated implantation failures and its pharmacological correction by the secretome of peri­pheral blood mono­nuclear cells. Russian Journal of Human Reproduction. 2024;(5):46-54
Immu­nological aspe­cts of reccurent pregnancy loss. Russian Journal of Human Reproduction. 2024;(5):64-71
Glial fibrillary acidic protein: is there a rela­tionship with the course of multiple scle­rosis and traumatic brain injury before the onset of multiple scle­rosis?. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):80-84
An indi­vidual approach to the diagnosis and treatment of an acute psychotic condition in a patient with a multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):97-102
Surgical treatment of seco­ndary trigeminal neuralgia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):203-209
Pecu­liarities of placental microRNA expression in patients with preeclampsia and fetal growth restriction. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):14-25
Changes in the type of psychological component of the gestational domi­nant in pregnant women in the third trimester after completing the peri­natal preparation program. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):66-71
Sexual function of women during pregnancy. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):112-117
Dyna­mics of Substance P and Fila­ggrin Levels on Combined Treatment of Atopic Dermatitis with Emollient and Topi­cal Anti­pruritic Drug in Pregnant Women. Russian Journal of Clinical Dermatology and Vene­reology. 2024;(6):662-666
Functional cyto­kine redu­ndancy in pregnancy. Russian Journal of Human Reproduction. 2024;(6):73-80
Abstract:

Planning for pregnancy and possibility of disease modifying treatment (DMTs) is an important question in female patients of reproductive age who suffer from multiple sclerosis (MS). The frequency of refusals to plan pregnancy is 14%. This is due to numerous concerns about the course of pregnancy, its outcomes, as well as the possible effect of DMTs on the fetus and the probability of disease transmission to a child. The article discusses immunological reactions taking place in MS patients during pregnancy, which are protective in its nature. Data for all groups of DMTs regarding pregnancy planning, possible risks of their impact on fertility and teratogenicity is presented.

Keywords:

multiple sclerosis
pregnancy
immunopathological mechanisms in pregnancy
disease-modifying treatment

Authors:

Zakroyshchikova I.V.

Research center of Neurology

Simaniv T.O.

Research Center of Neurology

Zemlyanaya D.O.

Pirogov Russian National Research Medical University

Timofeeva A.A.

Pirogov Russian National Research Medical University

Zakharova M.N.

Research Center of Neurology

Received:

17.05.2024

Accepted:

21.05.2024

Close metadata

References:

  1. Coyle PK. What Can We Learn from Sex Differences in MS? J Pers Med. 2021;11(10):1006. https://doi.org/10.3390/jpm11101006
  2. Bonavita S, Lavorgna L, Worton H, et al. Family planning decision making in people with multiple sclerosis Front Neurol. 2021;12:620772. https://doi.org/10.3389/fneur.2021.620772
  3. Houtchens M, Edwards N, Phillips A. Relapses and disease-modifying drug treatment in pregnancy and live birth in US women with MS. Neurology. 2018;91(17):e1570-e1578. https://doi.org/10.1212/WNL.0000000000006382
  4. Varytė G, Zakarevičienė J, Ramašauskaitė D, et al. Pregnancy and Multiple Sclerosis: An Update on the Disease Modifying Treatment Strategy and a Review of Pregnancy’s Impact on Disease Activity. Medicina. 2020;56(2):49.  https://doi.org/10.3390/medicina56020049
  5. Iakushina TI, Belova IuA. Cases of pregnancy in patients with aggressive multiple sclerosis treated with natalizumab. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(2-2):94‐97. (In Russ.). https://doi.org/10.17116/jnevro20191192294
  6. Spence R, Voskuhl R. Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front neuroendocrinol. 2012;33(1):105-115.  https://doi.org/10.1016/j.yfrne.2011.12.001
  7. Spanier J, Nashold F, Mayne C, et al. Vitamin D and estrogen synergy in Vdr-expressing CD4(+) T cells is essential to induce Helios(+)FoxP3(+) T cells and prevent autoimmune demyelinating disease. J Neuroimmunol. 2015;286:48-58.  https://doi.org/10.1016/j.jneuroim.2015.06.015
  8. Nashold F, Spach K, Spanier J, et al. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol. 2009;183(6):3672-3681. https://doi.org/10.4049/jimmunol.0901351
  9. Avila M, Bansal A, Culberson J, et al. The Role of Sex Hormones in Multiple Sclerosis. Eur Neurol. 2018;80(1-2):93-99.  https://doi.org/10.1159/000494262
  10. Hayrabedyan S, Shainer R, Yekhtin Z, et al. Synthetic PreImplantation Factor (sPIF) induces posttranslational protein modification and reverses paralysis in EAE mice. Sci Rep. 2019;9(1):12876. https://doi.org/10.1038/s41598-019-48473-x
  11. Gold SM, Sasidhar MV, Morales LB, et al: Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest. 2009;89(10):1076-1083. https://doi.org/10.1038/labinvest.2009.79
  12. Alroughani R, S. Akhtar M, Zeineddine Y, et al. Risk of relapses during pregnancy among multiple sclerosis patients. Mult Scler Relat Disord. 2019;34:9-13.  https://doi.org/10.1016/j.msard.2019.06.007
  13. Gavoille A, Rollot F, Casey R, et al. Investigating the long-term effect of pregnancy on the course of multiple sclerosis using causal inference, Neurology. 21;100(12):e1296-e1308. https://doi.org/10.1212/WNL.0000000000206774
  14. Jokubaitis V, Spelman T, Kalincik T, et al. Predictors of long-term disability accrual in relapse-onset multiple sclerosis, Ann Neurol. 2016;80(1):89-100.  https://doi.org/10.1002/ana.24682
  15. Portaccio E, Tudisco L, Pasto L, et al. Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening. Mult Scler. 2022;28(3):472-479.  https://doi.org/10.1177/13524585211023365
  16. Coyle PK. Management strategies for female patients of reproductive potential with multiple sclerosis: An evidence-based review. Mult Scler Relat Disord. 2019;32:54-63. 
  17. Krysko K. Patients of reproductive potential with multiple sclerosis Ther Adv Neurol Disord. 2020;13:1756286420936166.
  18. MacDonald SC, McElrath TF, Hernandez-Diaz S, Pregnancy outcomes in women with multiple sclerosis. Am J Epidemiol. 2019;188(1):57-66.  https://doi.org/10.1093/aje/kwy197
  19. Lopez-Leon S, Geissbuhler Y, Sabido M, et al. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. J Neurol. 2020;267(9):2721-2731. https://doi.org/10.1007/s00415-020-09913-1
  20. Carta A, Zarbo I, Scoppola C, et al. Maternal multiple sclerosis is not a risk factor for neurodevelopmental disorders in offspring. Mult Scler J Exp Transl Clin. 2021;7(2):20552173211017301. https://doi.org/10.1177/20552173211017301
  21. Wind M. multiple sclerosis and pregnancy. Eur J Obstet Gynecol Reprod Biol. 2021;260:29-36.  https://doi.org/10.1016/j.ejogrb.2021.02.027
  22. Coyle P. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9(3):198-210. 
  23. Dobson R. UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines. Pract Neurol. 2019:19:106-114. 
  24. Wang Y, Wang J, Feng J. Multiple sclerosis and pregnancy: Pathogenesis, influencing factors, and treatment options. Autoimmun Rev. 2023;22(11):103449. https://doi.org/10.1016/j.autrev.2023.103449
  25. Langer-Gould AM. Pregnancy and Family Planning in Multiple Sclerosis. Continuum (Minneap Minn). 2019;25(3):773-792).
  26. Voge NV, Alvarez E. Monoclonal Antibodies in Multiple Sclerosis: Present and Future. Biomedicines. 2019;7(1):20.  https://doi.org/10.3390/biomedicines7010020
  27. Hellwig K, Verdun di Cantogno E, Sabidó M. A systematic review of relapse rates during pregnancy and postpartum in patients with relapsing multiple sclerosis. Ther Adv Neurol Disord. 2021;14:17562864211051012. https://doi.org/10.1177/17562864211051012
  28. Nguyen AL, Havrdova EK, Horakova D, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord. 2019;28:235-243.  https://doi.org/10.1016/j.msard.2019.01.003
  29. Rasmussen PV, Magyari M, Moberg JY, et al. Patient awareness about family planning represents a major knowledge gap in multiple sclerosis. Mult Scler Relat Disord. 2018;24:129-134.  https://doi.org/10.1016/j.msard.2018.06.006
  30. Kaplan TB. Management of Demyelinating Disorders in Pregnancy. Neurol Clin. 2019;37(1):17-30.  https://doi.org/10.1016/j.ncl.2018.09.007
  31. Vukusic S, Michel L, Leguy S, et al. Pregnancy with multiple sclerosis. Rev Neurol (Paris). 2021;177(3):180-194.  https://doi.org/10.1016/j.neurol.2020.05.005
  32. Hakkarainen KM, Juuti R, Burkill S, et al. Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden. Ther Adv Neurol Disord. 2020;13:1756286420951072. https://doi.org/10.1177/1756286420951072
  33. Bove RM, Houtchens MK. Pregnancy Management in Multiple Sclerosis and Other Demyelinating Diseases. Continuum (Minneap Minn). 2022;28(1):12-33.  https://doi.org/10.1212/CON.0000000000001108
  34. Ciplea AI, Langer-Gould A, Stahl A, et al. Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e757.
  35. Herbstritt S, Langer-Gould A, Rockhoff M, et al. Glatiramer acetate during early pregnancy: A prospective cohort study. Mult Scler. 2016;22(6):810-816.  https://doi.org/10.1177/1352458515623366
  36. Bove R, Sutton P, Nicholas J. Women’s Health and Pregnancy in Multiple Sclerosis. Neurol Clin. 2024;42(1):275-293.  https://doi.org/10.1016/j.ncl.2023.07.004
  37. Sandberg-Wollheim M, Neudorfer O, Grinspan A, et al. Pregnancy Outcomes from the Branded Glatiramer Acetate Pregnancy Database. Int J MS Care. 2018;20(1):9-14.  https://doi.org/10.7224/1537-2073.2016-079
  38. Kaplan S, Zeygarnik M, Stern T. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding. Drug Saf. 2022;45(4):345-357.  https://doi.org/10.1007/s40264-022-01168-1
  39. Ciplea AI, Kurzeja A, Thiel S, et al. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis — COBRA study. Mult Scler. 2022;28(10):1641-1650. https://doi.org/10.1177/13524585221083982
  40. Hellwig K, Rog D, McGuigan C, et al. Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry. Neurol Neuroimmunol Neuroinflamm. 2021;9(1):e1114. https://doi.org/10.1212/NXI.0000000000001114
  41. Ciplea AI, Datta P, Rewers-Felkins K, et al. Dimethyl fumarate transfer into human milk. Ther Adv Neurol Disord. 2020;13:1756286420968414. https://doi.org/10.1177/1756286420968414
  42. Leroy C, Rigot JM, Leroy M, et al. Immunosuppressive drugs and fertility. Orphanet J Rare Dis. 2015;10:136.  https://doi.org/10.1186/s13023-015-0332-8
  43. Guarnaccia JB, Cabot A, Garten LL, et al. Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis. Mult Scler Relat Disord. 2022;57:103347. https://doi.org/10.1016/j.msard.2021.103347
  44. Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22(4):350-366.  https://doi.org/10.1016/S1474-4422(22)00426-4
  45. Vukusic S, Coyle PK, Jurgensen S, et al. Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Mult Scler. 2020;26(7):829-836.  https://doi.org/10.1177/1352458519843055
  46. Varytė G, Arlauskienė A, Ramašauskaitė D. Pregnancy and multiple sclerosis: an update. Curr Opin Obstet Gynecol. 2021;33(5):378-383.  https://doi.org/10.1097/GCO.0000000000000731
  47. Zhen Y. Natalizumab, Fingolimod and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis. Neurology. 2021;96(24):e2989-e3002. https://doi.org/10.1212/WNL.0000000000012084
  48. Doriana L. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022;34:34-38.  https://doi.org/10.1136/jnnp-2022-329657
  49. Vukusic S, Carra-Dalliere C, Ciron J, et al. Pregnancy and multiple sclerosis: 2022 recommendations from the French multiple sclerosis society. Mult Scler. 2023;29(1):11-36.  https://doi.org/10.1177/13524585221129472
  50. Undine P. Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. Front Immunol. 2021;12:715195. https://doi.org/10.3389/fimmu.2021.715195
  51. Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674-680.  https://doi.org/10.1212/WNL.0000000000000137
  52. Pauliat E, Onken M, Weber-Schoendorfer C, et al. Pregnancy outcome following first-trimester exposure to fingolimod: A collaborative ENTIS study. Mult Scler. 2021;27(3):475-478.  https://doi.org/10.1177/1352458520929628
  53. Callens A, Leblanc S, Le Page E, et al. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study. Mult Scler Relat Disord. 2022;66:104066. https://doi.org/10.1016/j.msard.2022.104066
  54. Bianco A, Lucchini M, Totaro R, et al. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients. Neurotherapeutics. 2021;18(4):2598-2607. https://doi.org/10.1007/s13311-021-01106-6
  55. Rowles WM, Hsu WY, McPolin K, et al. Transitioning From S1P Receptor Modulators to B Cell-Depleting Therapies in Multiple Sclerosis: Clinical, Radiographic, and Laboratory Data. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e1183. https://doi.org/10.1212/NXI.0000000000001183
  56. Almas S, Vance J, Baker T, Hale T. Management of Multiple Sclerosis in the Breastfeeding Mother. Mult Scler Int. 2016;2016:6527458. https://doi.org/10.1155/2016/6527458
  57. Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594-1604. https://doi.org/10.1177/1352458517727603
  58. Dost-Kovalsky K, Thiel S, Ciplea AI, et al. Cladribine and pregnancy in women with multiple sclerosis: The first cohort study. Mult Scler. 2023;29(3):461-465.  https://doi.org/10.1177/13524585221131486
  59. Giovannoni G, Galazka A, Schick R, et al. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Saf. 2020;43(7):635-643.  https://doi.org/10.1007/s40264-020-00948-x
  60. Datta P, Ciplea AI, Rewers-Felkins K, et al. Cladribine transfer into human milk: A case report. Mult Scler. 2021;27(5):799-801.  https://doi.org/10.1177/1352458520912173
  61. Khan E, Kagzi Y, Elkhooly M, et al. Disease modifying therapy and pregnancy outcomes in multiple sclerosis: A systematic review and meta-analysis. J Neuroimmunol. 2023;383:578178. https://doi.org/10.1016/j.jneuroim.2023.578178
  62. Steingo B, Al Malik Y, Bass AD, et al. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020;267(11):3343-3353. https://doi.org/10.1007/s00415-020-09983-1
  63. Li Z, Richards S, Surks HK, Jacobs A, et al. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol. 2018;194(3):295-314.  https://doi.org/10.1111/cei.13208
  64. Oh J, Achiron A, Celius EG, et al. Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years. Mult Scler Relat Disord. 2020;43:102146. https://doi.org/10.1016/j.msard.2020.102146
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.